(RTTNews) - Johnson & Johnson (JNJ) reported three-year data showing sustained clinical and endoscopic remission with Tremfya (guselkumab) in adults with moderately to severely active Crohn's disease.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.